Gador

Gador is an argentine private pharmaceutical company incorporated in 1940. The company has a turnover in Argentina of over USD100 million, and sells finished products (from its own plants approved by MERCOSUR authorities) and active principles (from its own plants approved by FDA and EMEA authorities) in the five continents in more than 30 countries. For over fifty years, Gador has represented licences from Astellas (former Fujisawa), Gilead, Recordati and Eli Lilly among others. Gador is also involved in pharmaceutical distribution (under a partnership in Farmanet S.A. with Novartis, Boehringer Ingelheim, and other argentine companies). In the area of R&D, with a long-standing relationship and scientific collaboration with the University of Leiden (Holland) and Argentine universities, a new molecule is under development for bone diseases, INN: Olpadronate. The clinical assays carried out in Holland as well as in Argentina have proved to have a high effectiveness and tolerance in the treatment of Paget bone disease as well in other orphan diseases. Gador is one of only five companies worldwide doing R&D in the bisphosphonates area, holding a strong portfolio of patents and IP rights. More than 20 years ago, Gador started research in Chagas disease. As a result of these efforts, Gador developed and produced the first commercial biotech diagnostic kit worldwide for the detection of Chagas disease, containing a mix of recombinant antigens of Trypanosoma cruzi.